REGENXBIO Price to Free Cash Flow Ratio 2014-2021 | RGNX

Historical price to free cash flow ratio values for REGENXBIO (RGNX) since 2014. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
REGENXBIO Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-21 24.91 0.00
2021-09-30 41.92 $-3.56 0.00
2021-06-30 38.85 $-3.29 0.00
2021-03-31 34.11 $-2.81 0.00
2020-12-31 45.36 $-2.17 0.00
2020-09-30 27.52 $-3.50 0.00
2020-06-30 36.83 $-3.33 0.00
2020-03-31 32.38 $-3.47 0.00
2019-12-31 40.97 $-3.26 0.00
2019-09-30 35.60 $-2.98 0.00
2019-06-30 51.37 $-2.67 0.00
2019-03-31 57.31 $-0.01 0.00
2018-12-31 41.95 $2.49 16.83
2018-09-30 75.50 $2.36 31.93
2018-06-30 71.75 $2.35 30.56
2018-03-31 29.85 $0.21 140.60
2017-12-31 33.25 $-2.18 0.00
2017-09-30 32.95 $-2.54 0.00
2017-06-30 19.75 $-2.50 0.00
2017-03-31 19.30 $-2.60 0.00
2016-12-31 18.55 $-2.15 0.00
2016-09-30 14.01 $0.13 111.90
2016-06-30 8.00 $-3.19 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.087B $0.155B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00